CD274 and gastric cancer: However, in the first-line treatment, the CheckMate-649 [36] trials showed an overall survival benefit of >3 months for GC patients with PD-L1 CPS ≥5 treated with a combination of oxaliplatin-fluoropyrimidine chemotherapy and nivolumab, and its clinical practice is likely to change.